QVA149: Additional Phase III data

Additional data from the double-blind, international Phase III SPARK trial in 2,224 patients with severe to very severe COPD showed that once-daily QVA149 significantly reduced the rate of moderate to severe COPD exacerbations from baseline to week 64, the primary endpoint, by 12% vs. once-daily 50 µg NVA237 (0.84 vs. 0.88 annual rate of exacerbations, p=0.038). QVA149 also significantly reduced the rate of all COPD exacerbations by 15% vs. NVA237 (p=0.0012) and by 14% vs. open-label 18 µg tiotropium (p=0.0017). Additionally, QVA149 significantly increased trough forced expiratory volume in 1 second (FEV1) vs. both NVA237 and tiotropium (p<0.0001 for both). Furthermore, QVA149 significantly improved health-related quality of life as measured St. George's Respiratory Questionnaire (SGRQ) scores vs. both NVA237 (p<0.01) and tiotropium (p<0.05). Data were published in The Lancet Respiratory Medicine. ...